Oruka's December Readout Will Test Whether Psoriasis Data Justify the Burn Rate

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Oruka Therapeutics has not disclosed the specific timing of its earnings release, but based on the absence of a time code in the data, the report is expected during market hours or after market close.

Oruka's post-earnings price behavior has been highly volatile, with an average absolute Day 0 move of 2.75% and an average Day +1 move of 6.65%—significantly larger than the Day 0 reaction. The most dramatic move came in March 2026, when the stock initially dropped 7.03% on earnings day but then surged 25.04% the following session, likely reflecting delayed investor reaction to clinical updates or analyst commentary.

The August 2026 earnings release saw the largest Day 0 move, with the stock jumping 6.40%, followed by a modest pullback the next day. In contrast, the November 2025 and May 2026 releases produced minimal Day 0 movement but saw notable Day +1 swings of -6.78% and +1.14%, respectively, suggesting that the market often takes time to digest Oruka's results and forward guidance.

The average Day 0 range of 7.07% and Day +1 range of 13.16% underscore the stock's sensitivity to clinical trial updates, cash burn commentary, and pipeline milestones. Given the heightened expectations around ORKA-001's progress and the upcoming Phase 3 timeline, investors should brace for significant volatility in both directions.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.10% expected move for Oruka through the November 20 expiration, which is below the stock's average historical Day +1 move of 6.65% but in line with the average Day 0 move of 2.75%. This suggests that options traders may be underestimating the potential for a delayed, outsized reaction—particularly given the stock's history of large Day +1 swings following earnings. With 10 days to expiration and average implied volatility of 96.97%, the options market is pricing in significant uncertainty, but the historical data suggests the actual move could exceed the expected range, especially if the company provides material updates on Phase 3 timelines or cash burn.

Part 3: What Analysts Are Saying

Oruka Therapeutics enjoys overwhelmingly bullish analyst sentiment, with a consensus rating of 4.87 out of 5.0—firmly in Strong Buy territory. Of the 15 analysts covering the stock, 14 rate it a Strong Buy and 1 rates it a Hold, with zero Sell ratings. This consensus has remained unchanged over the past month, reflecting sustained confidence in the company's clinical progress and commercial potential.

The average price target of $144.43 implies 31.9% upside from the current price of $109.50, with a wide range of estimates reflecting differing views on the timeline to commercialization and competitive positioning. The high target of $200.00 (82.6% upside) comes from Guggenheim, which has called ORKA-001 a potential multi-billion-dollar blockbuster. The low target of $105.00 (4.1% downside) suggests that even the most conservative analysts see limited downside risk at current levels.

The strength of the consensus is notable given the stock's 264% year-to-date surge. Analysts continue to cite the "best-in-class" EVERLAST-B data, the company's $1.2 billion cash position, and the potential for once-yearly dosing as key drivers of upside. However, the single Hold rating and the wide target range underscore the inherent uncertainty in valuing a pre-revenue biotech with no approved products and significant execution risk ahead of Phase 3 trials.

Analyst Ratings Summary:

• Strong Buys: 14 (unchanged from 1 month ago)
• Holds: 1 (unchanged from 1 month ago)
• Sells: 0
• Average Rating: 4.87 / 5.0
• Price Target Range: $105.00 – $200.00
• Mean Target: $144.43 (+31.9% upside)

Part 4: Technical Picture

Oruka Therapeutics is entering earnings with strong technical momentum and a bullish signal across all timeframes. The Barchart Technical Opinion currently stands at 72% Buy, up sharply from 56% Buy one week ago and 24% Buy one month ago, indicating a strengthening trend as the stock has rallied into the release.

The stock is trading above all key moving averages, a bullish configuration that underscores the strength of the recent rally:

• 5-day MA: $102.87 (above)
• 10-day MA: $99.88 (above)
• 20-day MA: $90.11 (above)
• 50-day MA: $88.82 (above)
• 100-day MA: $91.79 (above)
• 200-day MA: $71.59 (above)

This alignment suggests that both short-term and long-term buyers are in control, with the stock trading well above its 200-day moving average—a key indicator of a sustained uptrend.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive, though not at extreme levels, leaving room for further upside if earnings catalyze additional buying.
• Medium-term (50% Buy): Neutral-to-positive reading suggests consolidation in the intermediate timeframe, with the stock digesting recent gains while maintaining an upward bias.
• Long-term (100% Buy): Strong buy signal reflects robust conviction in the longer-term trend, consistent with the stock's 264% year-to-date surge and the market's belief in Oruka's clinical and commercial potential.

Trend Characteristics: The signal is characterized by Strong strength and a Strengthening direction, indicating that momentum is building heading into the earnings release.

The technical setup is supportive heading into earnings, with the stock trading above all major moving averages and the Barchart Opinion signal strengthening across all timeframes. The 100% Buy reading in the long-term timeframe reflects sustained institutional and retail interest, while the 50% Buy signals in the short- and medium-term suggest the stock is not yet overbought on a near-term basis.

Key levels to watch include the 20-day moving average at $90.11, which has acted as support during recent pullbacks, and the 50-day moving average at $88.82, which would represent a more significant retracement if tested. On the upside, the stock's recent high near $113 represents immediate resistance, with a breakout above that level potentially targeting the analyst consensus price target of $144.43.

Overall, the technical picture is constructive, with momentum favoring the bulls. However, given the stock's sharp rally and the inherent volatility around biotech earnings, investors should be prepared for significant two-way price action depending on the company's commentary around Phase 3 timelines, cash burn, and pipeline progress.